Article Information
History
- August 30, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Hirofumi Komaki1,2,†,
- Eri Takeshita1,2,†,
- Katsuhiko Kunitake3,†,
- Takami Ishizuka2,
- Yuko Shimizu-Motohashi1,
- Akihiko Ishiyama1,
- Masayuki Sasaki1,
- Chihiro Yonee4,
- Shinsuke Maruyama4,
- Eisuke Hida5 and
- Yoshitsugu Aoki3,*
- 1Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry (NCNP); Kodaira, Tokyo 187-8502, Japan
- 2Translational Medical Center, National Center of Neurology and Psychiatry (NCNP); Kodaira, Tokyo 187-8502, Japan
- 3Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP); Kodaira, Tokyo 187-8502, Japan
- 4Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University; Kagoshima City, Kagoshima 890-8520, Japan
- 5Department of Biostatistics and Data Science, Graduate School of Medicine, Osaka University; Suita-Shi, Osaka 565-0871, Japan
- ↵*Corresponding author. Email: tsugu56{at}ncnp.go.jp
Posted August 30, 2024.
Phase I/II Trial of Brogidirsen: Dual-Targeting Antisense Oligonucleotides for Exon 44 Skipping in Duchenne Muscular Dystrophy
